Ocular Therapeutix, Inc. (OCUL)

Market Cap	1.69B +37.8%
Revenue (ttm)	51.95M -18.5%
Net Income	-265.94M
EPS	-1.42
Shares Out	217.69M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,003,422
Open	6.99
Previous Close	7.03
Day's Range	6.99 - 8.00
52-Week Range	5.79 - 16.44
Beta	0.90
Analysts	Strong Buy
Price Target	22.33 (+187.02%)
Earnings Date	Feb 5, 2026

About OCUL

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 25, 2014
• Employees: 325
• Stock Exchange: NASDAQ
• Ticker Symbol: OCUL
• Website: https://www.ocutx.com

Financial Performance

In 2025, Ocular Therapeutix's revenue was $51.95 million, a decrease of -18.47% compared to the previous year's $63.72 million. Losses were -$265.94 million, 37.4% more than in 2024.

Analyst Summary

According to 10 analysts, the average rating for OCUL stock is "Strong Buy." The 12-month stock price target is $22.33, which is an increase of 187.02% from the latest price.

Price Target

$22.33

(187.02% upside)

Analyst Consensus: Strong Buy